COMPASS Pathways plc
CMPS
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$13.27
▼ -0.15%
P/E
-3.68
Mkt Cap
$1.8B
52-Wk Range
$4.82–$15.40
52-Week Range
$4.82 - $15.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 166.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary psilocybin formulation and delivery system (COMP360)
- Advanced clinical trial data and regulatory pathway expertise
- Integrated therapeutic protocol combining drug and psychotherapy
- Strong intellectual property portfolio protecting novel compounds and methods
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Stable outlook
Progression through FDA clinical trials toward regulatory approval
Value
Deep value opportunity - significant discount to Healthcare Facilities peers
Momentum
Strong
+13.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CMPS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 5, 2026
Reported EPS of -$1.88 vs -$0.39 consensus (-384.4% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-384.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
12 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 7, 2026
vs Industry
How CMPS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related